美康生物：公司生产经营正常

Group 1 - The core viewpoint of the article is that Meikang Bio (300439) is maintaining normal production and operations despite the trend of medical insurance cost control [1] - The company emphasizes the importance of effective management and fulfilling information disclosure obligations to enhance investor communication [1] - Meikang Bio aims to actively convey its investment value to the market [1]